The mission of Bayer Healthcare Pharmaceuticals is to research, develop and manufacture innovative diagnostic approaches and therapies so that diseases can be better identified and treated. At Bayer, oncology is more than just a therapeutic interest. Our singular vision is to improve the lives of those affected by cancer. As a global organization with widespread reach and impact, Bayer is applying its experience, knowledge and passion to make life better for oncology patients across the globe. We are dedicated to fulfilling our purpose of discovering innovative cancer-fighting therapies and providing personalized solutions as quickly as possible to patients and physicians with the ultimate goal of being able to treat cancer as a chronic disease. Through our global R&D capabilities, along with key strategic alliances, our passion, innovation, and dedication involved in these efforts are bringing to market products that carry hope, well being, and life to those impacted by cancer.
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail against serious diseases. Around the world, our medicines are helping millions of patients in their fight against such diseases as cancer, cardiovascular disease, diabetes, hepatitis B, HIV/AIDS, psychiatric disorders and rheumatoid arthritis. In addition, our philanthropic programs have given new hope to some of the world’s most vulnerable people.
Novartis Oncology delivers a broad range of innovative therapies aimed at improving and extending the lives of patients. These include Glivec® (imatinib), Tasigna® (nilotinib), Exjade® (deferasirox), Zometa® (zoledronic acid), Sandostatin® LAR® (octreotide/IM injection) and Femara® (letrozole). Novartis Oncology has a robust pipeline capitalizing on recent discoveries in molecular genomics, rational drug design and state-of-the-art drug discovery technologies.
Amgen discovers, develops, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing novel medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a broad and deep pipeline of potential new medicines, Amgen is committed to advancing science to dramatically improve people’s lives.
AngioDynamics is a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. Our diverse product line includes market-leading radiofrequency ablation and irreversible electroporation ablation systems, embolization products, vascular access products, dialysis products, and angioplasty products.
Biocompatibles is a leading medical technology company in the field of drug device combination products. Biocompatibles operates through an Oncology Products Division and two R&D businesses. Biocompatibles is pioneering the use of Drug-Eluting Beads for the treatment of Cancer and are developing other innovative products for Cancer and Diabetes.
Delcath Systems, Inc. has developed a platform technology, called Chemo Saturation, that isolates specific organs or regions of the body from the circulatory system and delivers high dose chemotherapy or other therapeutic agents to diseased organs or body regions, while protecting patients from toxicities that normally result from systemic exposure.
ILCA 2010 is supported by an educational grant from ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company.
MDS Nordion, headquartered in Ottawa, Canada is a global leader in providing products and services for medical imaging, radiotherapeutics and sterilization technologies for the prevention, diagnosis and treatment of disease. Our TheraSphere® product is a powerful yttrium-90 therapy used in the treatment of hepatic neoplasia.
OSI Pharmaceuticals is committed to “shaping medicine and changing lives” by discovering, developing and commercializing high-quality, novel and differentiated targeted medicines designed to extend life and improve the quality of life for patients with cancer and diabetes/obesity.
OSI Pharmaceuticals supports ILCA Junior Investigator Awards through an unrestricted educational grant.
Sirtex Medical Europe GmbH is a wholly-owned subsidiary of Sirtex Medical Limited, a publicly-listed company on the Sydney Stock Exchange engaged in the field of liver-directed therapies for oncology. Our innovative technology, SIR-Spheres® microspheres, was approved in 2002 for use in the treatment of unresectable liver tumours within the European Union under a CE Mark and for the treatment of colorectal cancer liver metastases in combination with FUDR intra-arterial chemotherapy by the US Food & Drug Administration. SIR-Spheres microspheres are presently used to treat a variety of unresectable liver metastases as well as in hepatocellular carcinoma at 52 European institutions.
Varian Medical Systems is the world’s leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices.